Crystalline form of 5(S)-(2-hydroxyethoxy)-20(S)-camptothecin

Details Crystalline form of 5(S)-(2-hydroxyethoxy)-20(S)-camptothecin Crystalline form of 5(S)-(2-hydroxyethoxy)-20(S)-camptothecin

2007-05-24

2009-10-13

Aulakh, Charanjit S (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S048000

Reexamination Certificate

active

07601732

ABSTRACT:
A crystalline form of 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer of 5(RS)-(2′-hydroxyethoxy)-20(S)-camptothecin is described that is characterized by having an X-ray powder diffraction pattern comprising one or more peak intensities expressed in degrees 2θ that are selected from the group consisting of 7.2±0.1, 9.4±0.1, 11.02±0.1, 12.00±0.1, 14.54±0.1, 15.2±0.1, 18.92±0.1, 21.86±0.1, 22.74±0.1 and 26.42±0.1. Methods of making and using the compound are also described.

REFERENCES:
patent: 6177439 (2001-01-01), Duvvuri et al.
Wall et al., Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata, Journal of the American Chemical Society, (1966), pp. 3888-3890, Volume-Issue 88:16, ACS Publications, Washington, DC.
Poynter et al., Coulometric Karl Fischer titration simplifies water content testing, Oil & Gas Journal, (1994), pp. 1-5, Volume-Issue 92:15, Kam Controls Inc., Houston, TX.
Monks, et al., Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines, Journal of the National Cancer Institute, (Jun. 5, 1991), pp. 757-766, Volume-Issue 83:11.
Stewart et al., Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice, Cancer Research, Oct. 15, 2004), pp. 7491-7499, Volume-Issue 64:2.
Gorlick et al., Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary, Clinical Cancer Research, (Nov. 15, 2003), pp. 5442-5453, vol. 9.
Benet et al., Appendix ll Design and Optimization of Dosage Regimens; Pharmacokinetic Data, Goodman & Goodman's the Pharmacological Basis of Therapeutics, Ninth Edition, pp. 1707-1711., 1996.
Alfonso R. Gennaro, Remington: The Science and Practice of Pharmacy, 20th Edition, (Lippincott, Williams and Wilkins), 2000.
John E. Hoover, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton Pennsylvania, Fifteenth Edition, 1975.
Liberman et al., Pharmaceutical Dosage Forms: Tablets vols. 1-3, Marcel Decker, New York, N.Y., 1980.
Kibbe et al., Handbook of Pharmaceutical Excipients, Third Edition, American Pharmaceutical Association, Washington, D.C., 1999.

Affiliated with

Also associated with

Rating

Crystalline form of 5(S)-(2-hydroxyethoxy)-20(S)-camptothecin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline form of 5(S)-(2-hydroxyethoxy)-20(S)-camptothecin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline form of 5(S)-(2-hydroxyethoxy)-20(S)-camptothecin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4128871